Unsplash+French pharma giant Servier is spending US$2.5bn to snap up Day One Biopharmaceuticals, gaining a key approved drug for difficult childhood brain tumours along with several promising pipeline candidates.
Tag Archive for: rare diseases
French biopharma THX Pharma has signed a strategic licensing deal with Biocodex, an independent French pharmaceutical group, to advance two drug candidates in three rare genetic disorders with high unmet need.
Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.
Swiss rare disease specialist VectivBio Holding AG is taking over US biotech Comet Therapeutics Inc. for an undisclosed amount. Comet focusses on treatments for metabolic diseases.